Patient-controlled intravenous analgesia enhanced recovery after surgery

Patient-controlled intravenous analgesia (PCIA) is an increasingly used method to control postoperative pain. The authors of a new article in BIO Integration aimed to investigate the association between PCIA and recovery after flap reconstruction in patients with oral squamous cell carcinoma (OSCC).,

iv fluid
Credit: Unsplash/CC0 Public Domain

Patient-controlled intravenous analgesia (PCIA) is an increasingly used method to control postoperative pain. The authors of a new article in BIO Integration aimed to investigate the association between PCIA and recovery after flap reconstruction in patients with oral squamous cell carcinoma (OSCC).

Patients with OSCC who underwent flap reconstruction between 2016 and 2020 were reviewed (n=850). Baseline characteristics were compared between PCIA and non-PCIA groups. Propensity score matching (PSM) (1:4) was introduced to eliminate these confounding factors (n=505). Univariate analysis was performed to compare matched PCIA and non-PCIA group. Univariate and multivariate analyses were performed before and after PSM to identify factors that influenced length of stay (LOS) in hospital. The differences in characteristics of matched and unmatched groups were also compared.

Before PSM, the differences in flap types, smoking status, and radiotherapy history between PCIA and non-PCIA groups were statistically significant (P

Patients with OSCC using PCIA after flap reconstruction surgeries have a reduced LOS in hospital compared with those who used conventional postoperative analgesic strategies. Moreover, postoperative glucose increase was lower in the PCIA group than in the non-PCIA group.


Explore further


More information:
Haojie Yang et al, Patient-controlled Intravenous Analgesia Enhanced Recovery After Surgery by Reducing Length of Hospital Stay in Patients with Oral Squamous Cell Carcinoma Who Underwent Flap Reconstruction: A Propensity Score-matched Study, BIO Integration (2021). DOI: 10.15212/bioi-2021-0018

Provided by
Compuscript Ltd

Leave a Reply